• >
  • >
  • >
  • >
  • >
Google > Case Studies > Google Cloud's AI Transforming Drug Discovery and Life Sciences with Generative AI

Google Cloud's AI Transforming Drug Discovery and Life Sciences with Generative AI

Google Logo
Customer Company Size
Large Corporate
Region
  • America
Country
  • United States
Product
  • Med-Gemini
  • Healthcare Data Engine
  • Vertex AI Search for Healthcare
Tech Stack
  • Generative AI
  • Machine Learning
  • Large Language Models (LLMs)
Implementation Scale
  • Enterprise-wide Deployment
Impact Metrics
  • Innovation Output
  • Cost Savings
  • Productivity Improvements
Technology Category
  • Analytics & Modeling - Generative AI
  • Analytics & Modeling - Machine Learning
  • Platform as a Service (PaaS) - Data Management Platforms
Applicable Industries
  • Life Sciences
  • Pharmaceuticals
Applicable Functions
  • Product Research & Development
  • Quality Assurance
Use Cases
  • Digital Twin
  • Predictive Quality Analytics
  • Remote Patient Monitoring
Services
  • Cloud Planning, Design & Implementation Services
  • Data Science Services
  • System Integration
About The Customer
Google Cloud is a leading provider of cloud computing services, offering a range of products and solutions designed to support various industries, including life sciences. The company has made significant investments in AI and machine learning, focusing on applications that can transform drug discovery and development. Google Cloud partners with organizations like Superluminal Medicines, Ginkgo Bioworks, and Bayer to leverage its advanced technologies for innovative biotech applications. These partnerships aim to enhance drug discovery efforts, streamline regulatory processes, and improve the management and analysis of complex healthcare data. Google Cloud's commitment to innovation and its extensive expertise in AI make it a key player in the life sciences sector, driving advancements that have the potential to significantly impact the industry.
The Challenge
The life sciences industry faces significant challenges in drug discovery, including the need for faster identification of promising drug targets and streamlined clinical trials. Traditional methods are often time-consuming and costly, limiting the speed at which new therapies can be brought to market. Additionally, there is a scarcity of data available to train algorithms, particularly in the rare disease space, which hampers the development of effective treatments. Companies like Bayer are also dealing with complex regulatory processes that require substantial automation to improve efficiency. The industry is in need of innovative solutions that can leverage advanced technologies like AI and machine learning to overcome these hurdles and accelerate the drug development process.
The Solution
Google Cloud is leveraging its advanced AI and machine learning capabilities to transform drug discovery and development in the life sciences industry. The company has developed Med-Gemini, a family of advanced AI models specifically designed for medical applications, capable of processing and interpreting diverse data types within medical contexts. Google Cloud also offers specialized services like Healthcare Data Engine and Vertex AI Search for Healthcare, enabling life sciences organizations to manage and analyze complex healthcare data effectively. Through partnerships with companies like Superluminal Medicines, Google Cloud is accelerating drug discovery using AI-powered dynamic protein modeling. Superluminal's platform captures the dynamic behavior of proteins, creating candidate-ready compounds with unprecedented speed. Additionally, Google Cloud is collaborating with Ginkgo Bioworks to build large language models for diverse biotech applications, focusing on genomics, protein function, and cell engineering. Bayer is also working with Google Cloud to develop synthetic images for oncology and automate regulatory processes, significantly improving efficiency. These solutions demonstrate Google Cloud's commitment to leveraging AI to address the challenges faced by the life sciences industry, ultimately reducing time and cost in bringing new therapies to market.
Operational Impact
  • Google Cloud's AI models have shown early promise in faster identification of promising drug targets.
  • Superluminal's platform creates candidate-ready compounds with unprecedented speed using dynamic protein modeling.
  • Bayer's use of synthetic images has been extremely useful in oncology and radiology, addressing the scarcity of data for training algorithms.
Quantitative Benefit
  • Superluminal Medicines launched with a $33 million seed round.
  • Bayer has automated 70 to 80% of their regulatory dossiers.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

Related Case Studies.

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that AGP may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from AGP.
Submit

Thank you for your message!
We will contact you soon.